Moderna Inc. is eyeing possible human testing of shots to fight mpox and bird flu this year, as the COVID-19 vaccine maker expands into more public-health immunizations.
The company is exploring messenger RNA vaccines for a number of such pathogens, most of them in the early stages of development, President Stephen Hoge said Monday in an interview. Moderna expects to advance its vaccines for mpox and bird flu to clinical trials after completing initial work on them, he said.
